News and Features
Food and Drug Administration (FDA) Approves Low-Dose Kaletra for HIV-Infected Children
This week the FDA approved a lower dose formulation of Kaletra (lopinavir/ritonavir) intended for use in children. The drug is expected to be available in the United States later this month.
Earlier this year, a warning on dosing of the liquid formulation of Kaletra was issued after an infant died from accidentally being given 10 times the recommended dose of the drug.
- At-a-Glance: "Dear Healthcare Provider Letter Issued on Use of Lopinavir/Ritonavir in Children"
- AIDSinfo: Pediatric Treatment Guidelines
- AIDSinfo: Lopinavir/ritonavir drug fact sheet
- AIDSinfo: Lopinavir/ritonavir clinical trials
National Institute of Allergy and Infectious Diseases (NIAID) Offers Workshop for HIV/AIDS Researchers
In conjunction with the Keystone Symposia "HIV Pathogenesis" and "HIV Vaccines," NIAID, the Division of AIDS, and the NIH Office of AIDS Research will sponsor a workshop for new investigators and postdoctoral fellows and trainees.
The workshop, set to begin on March 27, will provide attendees with the opportunity to develop grant writing skills, network with leading HIV/AIDS researchers, and promote collaborations for HIV/AIDS research projects.
Early registration is recommended. More information is available here.